Send to

Choose Destination
Diabetes Res Clin Pract. 2019 Sep 17;156:107864. doi: 10.1016/j.diabres.2019.107864. [Epub ahead of print]

Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study.

Author information

Hospital Regional de Alta Especialidad del Bajío, University of Guanajuato, León, Guanajuato, Mexico. Electronic address:
Hospital Regional de Alta Especialidad del Bajío, León, Guanajuato, Mexico.



Post-renal-transplanted patients frequently present hyperglycemia immediately after the procedure. The goal of this work was to evaluate the effect of linagliptin + insulin in post-renal-transplanted patients with hyperglycemia.


Retrospective comparative study in post-renal transplanted patients with hyperglycemia after transplantation who were treated with linagliptin 5 mg daily plus insulin vs insulin alone for 5 days after renal transplantation with hyperglycemia. Main outcomes were glucose levels, insulin dose and severity of hypoglycemia.


There were 14 patients treated with linagliptin + insulin and 14 patients treated only with insulin. Glucose levels and insulin doses were lower in the linagliptin + insulin group in comparison with the insulin alone group, 131.0 ± 15.1 vs 191.1 ± 22.5 mg/dl (7.27 ± 0.84 vs 10.61 ± 1.25 mmol/l) and 37.5 ± 6.3 vs 24.2 ± 6.6 U, respectively (p < 0.05). Hypoglycemia was less severe in the linagliptin + insulin group, 65.1 ± 2.2 vs 54.2 ± 3.3 mg/dl (3.61 ± 0.12 vs 3.00 ± 3.3 ± 0.18 mmol/l), p 0.036.


The combination of linagliptin + insulin provided better glycemic control with a lower insulin dose and less severe hypoglycemia in comparison to insulin alone in patients with hyperglycemia immediately after renal transplantation.


Hyperglycemia; Linagliptin; Renal transplantation

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center